콘텐츠로 건너뛰기
Merck
  • Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.

Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.

Arzneimittel-Forschung (2010-01-30)
Fan Xu, Yongping Qing, Beicheng Shang, Maozhi Liang, Yuangao Zou, Guili Xu
초록

To study the pharmacokinetics of acamprosate calcium (CAS 77337-73-6) in healthy Chinese subjects after oral administration of three dosage levels, 12 healthy subjects were divided into three groups and given a single oral dose of 333 or 666 or 1332 mg acamprosate calcium (enteric coated tablet). A sensitive liquid chromatography-tandem mass spectrometry method (LC-MS-MS) was used for the determination of acamprosate calcium in plasma. Both, a non-compartmental and compartmental method were used for analysis of kinetics parameters. The main pharmacokinetic parameters of the 333, 666 and 1322 mg regimen groups were as follows: tmax 7.5 +/- 2.6 h, 7.4 +/- 2.2 h, 8.1 +/- 3.1 h, Cmax 134.8 +/- 103.9 ng/mL, 297.5 +/- 188.1 ng/mL, 385.4 +/- 155.7 ng/mL, t1/2 13.3 +/- 11.4 h, 17.9 +/- 18.1 h, 15.1 +/- 9.1 h, AUC(0-t) 1772 +/- 1323 ng x h/mL, 3709 +/- 1195 ng x h/mL, 6421 +/- 2486 ng x h/mL, respectively. Statistical analysis of AUC/D showed that AUCs increased linearly with the administered dose. The kinetic process of acamprosate calcium was best fitted to a one-compartment model.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Acamprosate calcium, ≥98% (HPLC), powder